Supplementary Figure S9 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Q: What type of study is this?

This is a RCT study (also classified as: Phase 2, Human Clinical Trial).

Chang Gon Kim; Min Hee Hong; Dahee Kim; Brian Hyohyoung Lee; Hyunwook Kim; Chan‐Young Ock; Geoffrey Kelly; Yoon Ji Bang; Gamin Kim; Jung Eun Lee; Chaeyeon Kim; Se‐Heon Kim; Hyun Jun Hong; Young Min Park; Nam Suk Sim; Heejung Park; Jin Woo Park; Chang Geol Lee; Kyung Hwan Kim; Goeun Park; Inkyung Jung; Dawoon Han; Jong Hoon Kim; Junha Cha; Insuk Lee; Mingu Kang; Heon Song; Chiyoon Oum; Seulki Kim; Sukjun Kim; Yoojoo Lim; Seunghee Kim‐Schulze; Miriam Mérad; Sun Och Yoon; Hyun Je Kim; Yoon Woo Koh; Hye Ryun Kim

doi:10.1158/1078-0432.29996649

Key Points

The phase II trial demonstrates the immune response to combinations of durvalumab and tremelimumab in cancer treatment.
Immunohistochemistry reveals significant tumor-infiltrating T cells, indicating heightened immune activity post-treatment.
Open-label design allows for direct assessment of treatment effects on T cell presence and tumor response.
Findings suggest potential improvements in outcomes for patients with head and neck squamous cell carcinoma.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Open-label randomized clinical trial evaluates T cell infiltration in head and neck cancer, suggesting immunotherapy combinations may enhance treatment effectiveness.

Abstract

Enumerization of tumor-infiltrating T cells by immunohistochemostry stain.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2025) studied this question.

synapsesocial.com/papers/68bb3a352b87ece8dc954cc7 https://doi.org/10.1158/1078-0432.29996649

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S9 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S9 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers